<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Simon, Daniel I.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Inflammation and Vascular Injury</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">The focus this article is on a class of leukocyte adhesion molecules, leukocyte β2-integrins, among which Mac-1 (aMb2, CD11b/CD18) is the most common integrin on neutrophils. The leukocyte Mac-1 receptor interacts with the glyocoprotein Iba (GPIba) receptor on platelets, thereby regulating pro-inflammatory and pro-thrombotic bidirectional signals in both inflammatory cells and platelets.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>